Anakinra 100 mg

DRUG2 trials

Sponsors

Virginia Commonwealth University, Swedish Orphan Biovitrum

Conditions

Acute Gouty ArthritisAcute Myocardial Infarction

Phase 2

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

CompletedNCT01950299

Virginia Commonwealth UniversityAcute Myocardial Infarction

Start: 2014-07-01End: 2018-12-23Updated: 2019-12-18

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

CompletedNCT03002974

Swedish Orphan BiovitrumAcute Gouty Arthritis

Start: 2016-12-31End: 2019-08-31Updated: 2020-07-15

Related Papers

Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction.

2020-03-03225 citations

P6388Effects of Interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction on recurrent ischemic events: results from the VCUART3 study

European Heart Journal2019-10-011 citations

253Effects of Interleukin-1 blockade with Anakinra on cardiac function in ST-segment elevation acute myocardial infarction: results from the VCUART3 echocardiography study

European Heart Journal2019-10-011 citations

5947Predictive role of C-reactive protein levels in patients with ST-segment elevation acute myocardial infarction for heart failure related events

European Heart Journal2019-10-01

5233Interleukin-1 blockade with Anakinra in ST-segment elevation acute myocardial infarction: Results from the VCUART3 study

European Heart Journal2019-10-01

Rationale and design of the Virginia Commonwealth University–Anakinra Remodeling Trial‐3 (VCU‐ART3): A randomized, placebo‐controlled, double‐blinded, multicenter study

Clinical Cardiology2018-07-2351 citations